What makes a good antibody-drug conjugate?

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy, with a growing number of approved agents.
• The intricate structure of ADCs, comprising antibody, linker, and payload, offers numerous design considerations.

Purpose of the Study:

• To provide a comprehensive overview of recent developments in ADC structural components.
• To analyze current trends in ADC design within the clinical landscape.
• To offer expert insights into the future of ADC development and application.

Main Methods:

• Review of current clinical landscape and developmental trends in ADC technology.
• Analysis of advancements in antibody, linker, and payload components of ADCs.
• Synthesis of expert opinion on structure-function relationships and future prospects.

Main Results:

• Significant progress has been made in understanding ADC structure-function relationships.
• Improved design strategies are emerging, addressing historical setbacks and discontinuation rates.
• The therapeutic potential of ADCs is expanding to novel targets and indications.

Conclusions:

• A deep understanding of ADC structure-function is crucial for translating design advances into clinical success.
• Continued innovation in ADC components will drive broader applications in oncology.
• The future of ADCs involves targeting new indications with novel payloads and antibodies.